HomeFile

File

View Category
Antiplatelet

Cardiovascular Risk, Dual Antiplatelet Therapy, and Age. What Should We Know?

Non-adherence to dual antiplatelet therapy varies with age and patients older than 75 years old are those...
solaci -
Learn More
Structural heart disease

Safe for 80-Year-Olds. Should Nonagenarians be Withheld from TAVR?

According to this large global registry, mortality after transcatheter aortic valve replacement (TAVR) is twice as high...
solaci -
Learn More
Structural heart disease

Outpatient Rhythm Monitoring After TAVR Could Save Us from Some Pacemakers?

Delayed high-grade block after transcatheter aortic valve replacement (TAVR) goes unnoticed in patients undergoing TAVR without prior...
solaci -
Learn More
Coronary disease

The Most Read Articles of may in Interventional Cardiology

1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs....
solaci -
Learn More
Femoropopliteal

Mortality and Paclitaxel Devices, Data Are Aligning

5 years ago, several prospective randomized studies confirmed paclitaxel coated balloons were safe and effective in femoropopliteal...
solaci -
Learn More
Structural heart disease

Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?

After post TAVR mean 3-year follow-up, a new onset persistent left bundle branch block (LBBB) was not...
solaci -
Learn More
Coronary disease

New Risk Factors: Air Pollution, Air Temperature, Pain, and Sleep Hours

Traditionally, we have used age, gender, obesity, hypertension, dyslipidemia, smoking, and diabetes as cardiovascular risk factors. However,...
solaci -
Learn More
Structural heart disease

Good News at 3 Years for “Valve-in-Valve”

In this new era, the paradigm to treat the whole spectrum of transcatheter aortic valve replacement (TAVR)...
solaci -
Learn More